Deferred Tax Assets, Valuation Allowance of Sage Therapeutics, Inc. from 31 Dec 2013 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Sage Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2024.
  • Sage Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $796,718,000, a 8.4% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Sage Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $796,718,000 +$61,524,000 +8.4% 31 Dec 2024 10-K 11 Feb 2025 2024 FY
Q4 2023 $735,194,000 +$141,908,000 +24% 31 Dec 2023 10-K 11 Feb 2025 2024 FY
Q4 2022 $593,286,000 +$122,682,000 +26% 31 Dec 2022 10-K 14 Feb 2024 2023 FY
Q4 2021 $470,604,000 +$94,501,000 +25% 31 Dec 2021 10-K 16 Feb 2023 2022 FY
Q4 2020 $376,103,000 -$107,169,000 -22% 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q4 2019 $483,272,000 +$174,925,000 +57% 31 Dec 2019 10-K 24 Feb 2021 2020 FY
Q4 2018 $308,347,000 +$102,906,000 +50% 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q4 2017 $205,441,000 +$70,369,000 +52% 31 Dec 2017 10-K 19 Feb 2019 2018 FY
Q4 2016 $135,072,000 +$66,003,000 +96% 31 Dec 2016 10-K 22 Feb 2018 2017 FY
Q4 2015 $69,069,000 +$40,766,000 +144% 31 Dec 2015 10-K 24 Feb 2017 2016 FY
Q4 2014 $28,303,000 +$15,564,000 +122% 31 Dec 2014 10-K 29 Feb 2016 2015 FY
Q4 2013 $12,739,000 31 Dec 2013 10-K 06 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.